
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc. is expected to maintain high single-digit organic growth as it expands its client base and implements contractual price escalators, targeting long-term margin expansion towards 20%. The company reported better-than-anticipated fourth-quarter results, supported by improvements in the Ignite platform and prospects for increased profitability. Additionally, the integration of both technology and professional services positions Health Catalyst favorably in the market, as evidenced by the signing of 32 new platform customers, which surpassed revised expectations, suggesting potential for future value creation for shareholders.
Bears say
Health Catalyst's stock faces a negative outlook primarily due to projected revenue declines and disappointing guidance for the upcoming quarters, with an expected organic revenue decrease of 2-3% for Q4 and a y/y decline ranging from 11.9% to 14.3% in Q1 2026, which is below consensus estimates. The transition towards the lower-cost Ignite platform has resulted in down-selling and potential customer attrition, exacerbated by economic uncertainties impacting the healthcare purchasing environment. Additionally, while the company is undertaking restructuring to mitigate some losses, the overall forecast for 2026 indicates further revenue reductions, contributing to concerns about future growth and profitability.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares